Vevye Now Available for Patients With Dry Eye Disease

Vevye^® (cyclosporine ophthalmic solution) 0.1% has been made available by Harrow for the treatment of the signs and symptoms of dry eye disease.

Vevye contains cyclosporine, a calcineurin inhibitor. According to the Company, the drug’s bioavailability is improved using its proprietary water-free technology. The product does not contain oils or surfactants and is preservative-free.

In clinical trials involving patients with dry eye disease, a significantly greater percentage of patients treated with Vevye had increases of 10mm or greater from baseline in Schirmer tear test score compared with vehicle. The most common adverse reactions reported were instillation reactions, which were mostly mild in severity.

Vevye is supplied in a 5mL multiple-dose eye drop bottle containing 2mL of solution. Each drop (0.01mL) delivers 0.01 mg of cyclosporine. If used with other topical ophthalmic drugs, the products should be administered at least 15 minutes apart.

“We are excited to see Vevye’s exceptional clinical trial data come to life as US dry eye disease patients are now able to access and experience a highly tolerable product that provides rapid onset of relief and sustained improvement of both signs and symptoms of dry eye disease,” said Mark L. Baum, Chairman and Chief Executive Officer of Harrow.

Harrow is offering a savings card for Vevye to eligible patients.